Related Experiment Video

Updated: Jun 29, 2026

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits (Oryctolagus cuniculus)
13:00

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits (Oryctolagus cuniculus)

Published on: July 31, 2021

Phase II meningococcal B vesicle vaccine trial in New Zealand infants

C Jackson1, D R Lennon, V T K Sotutu

  • 1The University of Auckland, Auckland, New Zealand.

Archives of Disease in Childhood
|October 8, 2008
PubMed

Insights

A meningococcal B vaccine developed against the New Zealand epidemic strain was safe and immunogenic in infants. Three doses of the candidate vaccine induced a sero-response in 74% of infants aged 6-8 months.

Area of Science:

  • Immunology
  • Vaccinology
  • Epidemiology

Background:

  • A meningococcal B epidemic in New Zealand was dominated by Neisseria meningitidis strain B:4:P1.7b,4.
  • A tailor-made outer membrane vesicle vaccine was developed against this epidemic strain.

Purpose of the Study:

  • To assess the safety, reactogenicity, and immunogenicity of a meningococcal B vaccine in infants aged 6-8 months.
  • To evaluate a candidate vaccine against the New Zealand epidemic strain (NZ98/254).

Main Methods:

  • An observer-blind, randomized, controlled trial was conducted in 296 healthy infants in Auckland, New Zealand.
  • Infants received three doses of the candidate meningococcal B vaccine or a meningococcal C conjugate vaccine at 6-weekly intervals.
  • Immune response was measured using a human complement-mediated serum bactericidal assay, with sero-response defined as a fourfold or greater rise in titre.

Main Results:

  • Three doses of the candidate meningococcal B vaccine resulted in a sero-response to strain NZ98/254 in 74% of vaccinees.
  • No recipients of the meningococcal C conjugate vaccine showed a sero-response to NZ98/254.
  • Both vaccines were well-tolerated, with no vaccine-related serious adverse events reported.

Conclusions:

  • The New Zealand candidate meningococcal B vaccine demonstrated safety and immunogenicity against the epidemic strain NZ98/254 in infants aged 6-8 months.
  • Three doses of the vaccine were effective in inducing a protective immune response.
Abstract

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Vaccinations01:51

Vaccinations

Overview